| Assessment Status | Rapid Review Complete |
| HTA ID | 25025 |
| Drug | Semaglutide |
| Brand | Wegovy® |
| Indication | Semaglutide 2.4 mg (Wegovy®) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with: ∙ obesity (Body Mass Index (BMI) ≥ 95th percentile as defined on sex and age-specific BMI growth charts) and ∙ body weight above 60 kg^ |
| Assessment Process | |
| Rapid review commissioned | 21/03/2025 |
| Rapid review completed | 01/05/2025 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that semaglutide not be considered for reimbursement at the submitted price*. |
^ The applicant is seeking reimbursement in a subpopulation of the licensed adolescent population, specifically:
- adolescent patients between the ages 12 and 17 years (inclusive) with a body weight above 60kg,
- with a BMI > 99.6th percentile,
- and two or more of the comorbidities as defined by Children’s Health Ireland (CHI) complex obesity referral form criteria.
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here.
Further information on the status of this decision may be found here.
